Oramed (ORMP) targets a new patient subset after FDA setback. Learn how promising trials may revive its protein oral delivery ...
Ultimately, I argued four of the cases, my co-counsel argued the other. But I would still have to prepare for the argument ...
With a cash buyout price anchoring the stock and orders still hitting records, this move looks less like a macro call and more like a wager on deal certainty and downside protection.
Elsewhere, HYBE made a push into Africa via a new partnership with Tyla’s managers Brandon Hixon and Colin Gayle. Also this ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback